27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Invitae Corp (NYSE:NVTA) has agreed to acquire consumer health technology company Ciitizen for $325 million in a bid to make it easier for patients to collect their genomic and clinical information.
- Ciitizen, backed by several investors, including a16z, Section 32, and Verily, is building a digital platform that will enable patients to collect, store, and share their medical records.
- Invitae has been expanding the genomic content of its testing platform and investing in software and data science capabilities to analyze patient data.
- Ciitizen can help it create a centralized hub for medical data to inform research and improve medical decision-making.
- Invitae said in a statement that it had raised more than $1.4 billion since the start of the year, which it plans to spend partly on acquiring new capabilities.
- Under the terms of the deal, Invitae will acquire Ciitizen for around $125 million in cash and about 7 million shares.
- Invitae will also issue approximately $225 million in restricted stock units to Ciitizen employees who join Invitae as part of the acquisition.
- Price Action: NVTA shares are down 0.61% at $31.05 during the market session on the last check Tuesday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!